tirzepatide fda announcement May 18, 2026: warns 503B compounding pharmacy for producing after shortage ended – Partnership for Safe Medicines BioCentury - Nov. 8 Quick

Cardiovascular and Vascular Benefits: GLP-1s can reduce the risk of major cardiovascular events, such as nonfatal heart attacks, nonfatal strokes, and cardiovascular deatheven in patients without diabetes

The scientists believe that this pathway could be an avenue by which GLP-1s treat other dysfunctions in reward processing such as substance use disorders

Research shows that those who skip multiple doses face challenges in maintaining weight loss, as the appetite-suppressing benefits of the drug diminish

Pregnant or nursing patients should avoid both interventions without explicit provider approval

Medical Aesthetics News Portland, OR July 24, 2026 By Cosmetiq Medicine A clinical review published this week put a number on something injectors have been watching for three years: the facial changes that follow rapid weight loss on GLP-1 medications are now driving measurable demand for aesthetic treatment

Semaglutide is a medication approved by the FDA for the treatment of type 2 diabetes and, more recently, for chronic weight management in adults with obesity or overweight conditions